Anti-PD-1 and regorafenib induce severe multisystem adverse events in microsatellite stability metastatic colorectal cancer: a case report.
Sign Up to like & getrecommendations! Published in 2021 at "Immunotherapy"
DOI: 10.2217/imt-2020-0327
Abstract: There exists a dilemma in the treatment of microsatellite stability (MSS) metastatic colorectal cancer (mCRC) owing to limited therapeutic options. Based on the promising results of the REGONIVO trial, combination of anti-PD-1 and regorafenib could… read more here.
Keywords: metastatic colorectal; anti regorafenib; microsatellite stability; colorectal cancer ... See more keywords